Compare Adaptive Biotechnologies Corp (ADPT) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sirius XM Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Sirius XM Holdings Inc trades at $28.38 (market cap $9.70B). The key difference: Sirius XM Holdings Inc is far larger — about 2.4× Adaptive Biotechnologies Corp's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SIRI | |
|---|---|---|
Market Cap | $4.04B | $9.70B |
Sector | Health | Media |
52-Week High | $25.45 | $32.59 |
52-Week Low | $12.30 | $19.92 |
Enterprise Value | $4.10B | $18.98B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Sirius XM Holdings (SIRI) trades at $28.275, down 1.75% today, with a bearish technical signal and mixed earnings history including a Q2 2026 miss. The company maintains stable cash flow, with Q2 revenue up 1% year-over-year and raised 2026 guidance. Valuation appears attractive with a P/E of 11.56 and P/B below 1, while a $0.27 dividend provides income support.
Outlook: SIRI offers value with solid fundamentals and shareholder returns, but faces competitive pressures and subscriber volatility. Risks include high debt and market sentiment shifts. Analysts see 17% upside to the $33.17 consensus target, supporting a cautious buy view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
